[Two Cases of Advanced Esophageal Cancer with Pathological Complete Response after Neoadjuvant Chemotherapy with...

We report 2 pathological complete response (pCR) cases of neoadjuvant UDON(5-fluorouracil, docetaxel, and nedaplatin)therapy without any adverse events in advanced esophageal squamous cell carcinoma. One patient was a 58-year-old man. He complained of dysphagia and was diagnosed with advanced mid-thoracic esophageal cancer (Mt, SCC, cT3rN1M0, cStage Ⅲ). After 3 courses of UDON therapy without any adverse events, mediastinoscopic radical esophagectomy was performed without any postoperative complications. The second patient was a 72-year-old man. Advanced esophageal cancer (Mt, SCC, cT3rN0M0, Stage Ⅱ)was detected during treatment for ischemic heart disease. After 2 courses of UDON therapy without any adverse events, including cardiac events, mediastinoscopic radical esophagectomy was performed without any postoperative complications. UDON therapy, which is similar to DCF(docetaxel, cisplatin, and 5-FU)therapy, comprises divided doses of docetaxel and nedaplatin, which minimizes adverse effects on the bone marrow, heart, and kidneys. UDON therapy may be a safe and effective regimen and a reasonable and recommended choice for older and high-risk patients with advanced esophageal cancer.